TB-500

Thymosin Beta-4 and its TB-500 fragment operate through multiple interconnected molecular mechanisms, organized here from most to least established:

Primary Mechanism: G-Actin Sequestration and Cytoskeletal Regulation

The defining biochemistry of Tβ4/TB-500 is its role as the primary G-actin sequestering protein in mammalian cells:

• Tβ4 binds G-actin (monomeric actin) in a 1:1 stoichiometric interaction with a dissociation constant (Kd) of approximately 0.5–0.7 μM — binding essentially all free G-actin in the cytoplasm​
• By maintaining this large reservoir of unpolymerized actin, Tβ4 acts as a cytoskeletal buffer — controlling the availability of actin monomers for F-actin (filamentous actin) assembly on demand
• When a cell receives a motility signal (injury chemokine, growth factor, mechanical cue), TB-500 releases sequestered G-actin into the polymerization machinery → rapid F-actin growth at the leading edge → cell shape change → directed migration toward the injury site
• The practical consequence: microinjection of Tβ4 into living epithelial cells and fibroblasts produced dose-dependent depolymerization of actin stress fibers within minutes — a direct demonstration of cytoskeletal control​
• The TB-500 heptapeptide (LKKTETQ) contains the minimal actin-binding motif LKKET sufficient for this G-actin interaction, though crystallographic analyses of the full Tβ4 protein show that essentially the entire 43-residue sequence participates in the actin binding interface through an extended contact surface​

Cell Migration — The Therapeutic Consequence of Actin Regulation

The clinical importance of G-actin regulation is entirely downstream of this motility effect:

• TB-500 accelerates migration of the three major cell types required for wound closure: keratinocytes (re-epithelialization of skin and mucosal surfaces), fibroblasts (ECM synthesis and collagen deposition), and endothelial cells (vascular tube formation and angiogenesis)
• Migration speed and directional persistence are significantly increased — in vitro models consistently show 1.5–3-fold improvements in scratch wound closure rates in TB-500-treated vs. control cells
• TB-500 upregulates matrix metalloproteinases (MMPs) at the wound edge, degrading surrounding ECM to create physical space for migrating cells while simultaneously signaling new ECM synthesis in the wound bed​
• The actin-regulation mechanism makes TB-500 uniquely suited to treating chronic non-healing wounds — including diabetic ulcers and aged tissue — where the cellular migration machinery is pathologically impaired; TB-500 restores migration competence in cells from both diabetic and aged animal models where baseline motility is severely reduced​

Angiogenesis — VEGF Pathway Activation and Endothelial Mobilization

TB-500 promotes formation of new blood vessels through two distinct mechanisms:

• Transcriptional activation: TB-500 upregulates expression of VEGF (Vascular Endothelial Growth Factor) and its receptor VEGFR2, providing a molecular angiogenic signal that is additive to BPC-157’s VEGFR2 activation mechanism
• Cell trafficking: TB-500’s actin regulation directly enables endothelial cell elongation, migration, and tubulogenesis — the physical construction of capillary tubes at the injury site requires the precise cytoskeletal remodeling that TB-500 facilitates
• HIF-1α interactions: TB-500 interacts with the hypoxia-inducible factor (HIF-1α) pathway, which senses low oxygen at injury sites and coordinates the angiogenic response​
• ILK-Akt survival signaling: Integrin-Linked Kinase activated by TB-500 drives Akt phosphorylation → cell survival in ischemic, nutrient-deprived wound environments — protecting endothelial cells and cardiomyocytes during the critical early window before vascular reperfusion

Anti-inflammatory and Anti-fibrotic Effects

TB-500 resolves inflammation through multiple pathways:

• NF-κB downregulation: TB-500 inhibits NF-κB nuclear translocation — reducing production of TNF-α, IL-1β, IL-6, and ICAM-1, the main cytokines driving chronic inflammation and tissue destruction
• Macrophage modulation: Tβ4 shifts macrophage polarization toward the M2 (anti-inflammatory, repair-promoting) phenotype — reducing local inflammatory cell density while maintaining adequate immune surveillance​
• Anti-fibrotic: A critical property that distinguishes TB-500 from anabolic peptides — it reduces myofibroblast numbers at wound sites, the cells responsible for scar tissue contraction and fibrosis, guiding matrix deposition toward organized collagen architecture rather than disorganized scar tissue
• TGF-β1/Smad pathway modulation: The Tβ4-derived Ac-SDKP metabolite specifically reduces TGF-β1 expression and Smad2/3 phosphorylation — the central fibrogenic signaling axis in cardiac, renal, pulmonary, and hepatic fibrosis

The Ac-SDKP Pathway — A Second Active Molecule Within TB-4

A critical mechanistic dimension not captured by TB-500 (the fragment) but present in the full Tβ4 molecule is the Tβ4 → Ac-SDKP enzymatic axis:

• The N-terminal four amino acids of Tβ4 (Ac-Ser-Asp-Lys-Pro, or Ac-SDKP) are sequentially cleaved from the parent molecule by two enzymes: first meprin-α (releases the dipeptide Ac-SD), then prolyl oligopeptidase (POP) (releases the final tetrapeptide Ac-SDKP)
• Ac-SDKP is a separately active pharmacological agent with its own receptor binding sites (identified in myocardium), its own anti-fibrotic and anti-inflammatory properties, and its own angiogenic effects — functioning in parallel with and independently from the main LKKTET actin-binding domain
• In plasma, Ac-SDKP is degraded by ACE (angiotensin-converting enzyme) — which is why ACE inhibitor treatment increases circulating Ac-SDKP 4–5-fold, likely contributing to ACE inhibitors’ anti-fibrotic cardiac effects beyond their blood pressure-lowering activity
• TB-500 (Ac-LKKTETQ) lacks the Ac-SDKP sequence entirely — it is a C-terminal fragment and does not contain the N-terminal Ac-SDKP tetrapeptide — meaning this entire anti-fibrotic/cardiovascular pathway is absent in TB-500 and is only present when using full-length Tβ4
• This distinction is clinically important: the cardiovascular and organ-fibrosis applications of Tβ4 may depend substantially on Ac-SDKP biology that the TB-500 fragment alone does not reproduce​

Functional Regions of the Tβ4 Molecule — Summary

TB-500 (Ac-LKKTETQ) captures the actin-binding domain only — providing the cell migration and cytoskeletal effects while the other functional regions are absent.

Thymosin Beta-4 has accumulated one of the most substantive translational research portfolios of any peptide in this catalog — from 1960s thymic biology through to 2020s cardiac clinical trials. The evidence is reviewed by domain:

Dermal Wound Healing

• Topical wound healing (animal models): Multiple studies demonstrate that topical TB4/TB-500 accelerates wound closure in murine and porcine models — a comprehensive animal studies review (Annals of the New York Academy of Sciences, 2010) summarized the preclinical evidence supporting dermal, corneal, and cardiac multicenter clinical trials
• Diabetic wound models: TB4 accelerated healing in db/db diabetic mice and aged mice, specifically restoring the pathologically impaired cellular migration response — evidence that TB-500 corrects the fundamental migration deficit underlying chronic non-healing wounds
• TB-500 wound contraction: A frequently cited preclinical study found wound healing 61% better in the TB-500 group than in saline controls, with 11% more significant wound contraction at day 7​

Corneal and Ocular Research — Most Advanced Human Evidence

The strongest human clinical evidence for Tβ4 comes from ophthalmology, where RegeneRx Biopharmaceuticals has conducted the most rigorous trials:

• Phase I IV safety trial (Wang et al., 2021, J Cell Mol Med): Enrolled 84 subjects across multiple dose cohorts of recombinant Tβ4 administered intravenously — single and multiple doses — with no dose-limiting toxicities and no serious adverse events. No obvious drug accumulation with continuous administration
• Phase II dry eye — RGN-259 (Sosne et al., 2013, physician-sponsored): 9 patients (18 eyes) with severe dry eye including GvHD received Tβ4 0.1% drops 6 times/day for 28 days. At day 56 (follow-up): Tβ4-treated group showed 35.1% reduction in ocular discomfort vs. vehicle (p=0.0141) and 59.1% reduction in corneal fluorescein staining (p=0.0108). No adverse events in either group​
• Phase II dry eye — RGN-259 (multicenter): 72 subjects randomized 1:1 to 0.1% Tβ4 or placebo for 28 days. Primary endpoints (inferior corneal staining, ocular discomfort) did not reach statistical significance; however, multiple secondary endpoints were significant: 27% reduction in CAE discomfort scores on day 28 (p=0.0244); significant improvements in central and superior corneal staining (p=0.0075, p=0.0210). No adverse events​
• Phase III trials: RegeneRx completed three Phase 3 trials in dry eye syndrome and is navigating the FDA regulatory pathway​
• Bacterial keratitis (2023): Tβ4 identified as a potential adjunct treatment for bacterial keratitis — reducing inflammation and accelerating corneal surface restoration as an adjunct to antibiotic therapy​

Cardiac Repair — Second Most Advanced Evidence Domain

• Myocardial infarction models (multiple species): In mouse ligation and pig ischemia-reperfusion models, systemic Tβ4 administration reduced infarct size, decreased cardiac fibrosis, improved ejection fraction, prevented cardiac rupture, and increased vessel density — one of the most reproducible and consistent preclinical cardiac repair findings in the peptide literature
• Acute phase: Tβ4 reduces infarct size and cardiomyocyte apoptosis in the first hours post-MI
• Chronic phase: Tβ4 activates growth of vascular and cardiac progenitor cells over subsequent weeks, contributing to long-term cardiac remodeling​
• REGENERATIVE-IHD Trial (2015, UK): The UK’s largest randomized, placebo-controlled cardiac stem cell trial found significant increase in circulating Tβ4 in stem cell-injected responders 24 hours post-injection; elevated Tβ4 was directly and significantly associated with improvement in cardiac symptoms at 6 months — the first published human evidence of Tβ4’s role in cardiac repair
• Heart attack pilot study (2016, RegeneRx): Pilot study priming stem cells with Tβ4 prior to reinjection in heart attack patients — improved exercise capacity and cardiac function at 6-month follow-up​
• Phase 2 AMI Trial (NCT05485818, NCT05984134): Multicenter Phase 2 randomized double-blind trial of Thymosin Beta-4 (NL005) in 90 STEMI patients following PCI, evaluating infarct size (CMR), LVEF, and microvascular obstruction at days 5 and 90 — completed with well-tolerated safety profile
• Porcine large-animal MI model (2021, Theranostics): Co-treatment with Tβ4 microspheres and hiPSC-derived cardiomyocytes in infarcted pig hearts improved LV systolic function, increased cardiomyocyte and endothelial cell proliferation, reduced ventricular arrhythmia, and — crucially — did not induce tumorigenesis
• Cardiac remodeling ROCK1 pathway (2025, IJMS): Tβ4 modulates cardiac remodeling by regulating ROCK1 expression via miR139-5p, attenuating pathological scarring in the infarcted heart — confirming ongoing mechanistic investigation of Tβ4’s cardiac anti-fibrotic pathways​

Musculoskeletal Applications

• Frontiers in Endocrinology (2021) comprehensive review: Established that Tβ4 accelerates healing in muscle, tendon, and ligament injuries by stimulating cell migration, increasing blood supply, and reducing scar tissue formation​
• Muscle and tendon: Improved healing of ligaments, muscle, and bone in animal models; specific effects on tendon fibroblast outgrowth and collagen alignment
• Cartilage and intervertebral disc: Evidence of improved regeneration of injured cartilage and intervertebral disc cells via Tβ4 administration​
• Anti-inflammatory joint protection: Tβ4’s NF-κB downregulation and anti-inflammatory properties are directly relevant to tendinopathy, arthritis, and chronic overuse injuries​
• The musculoskeletal data for TB-500 specifically (as opposed to full-length Tβ4) is more limited — most studies use the full-length recombinant protein, and the degree to which the LKKTETQ fragment reproduces these effects requires further characterization

Neuroprotection

• Tβ4 reduced neurological deficit scores and contusion volume in TBI models​
• Spinal cord injury: improved functional recovery in rat compression and contusion models​
• Peripheral nerve: promotes Schwann cell migration and myelination after nerve transection​
• Neurogenesis and CNS stem cell activation — some evidence of neurogenic potential in hippocampal models​

Anti-aging and Systemic Effects

• Tβ4 levels decline with age — restoring youthful Tβ4 signaling has been proposed as a mechanism for reversing age-related regenerative decline​
• Tβ4 promotes the survival of transplanted endothelial progenitor cells in the infarcted myocardium, increasing engraftment and vessel formation — relevant to cell therapy approaches​
• Potential role in ferroptosis inhibition — a 2021 study identified Tβ4 as an endogenous iron chelator and molecular switcher of ferroptosis, expanding its cytoprotective profile beyond classical apoptosis prevention​

Regulatory Status — FDA

The FDA’s regulatory position on TB-500 is unusually clearly documented:

• Category 2 (503A): FDA placed Thymosin beta-4, fragment (LKKTETQ) — TB-500 — on the Section 503A Category 2 list effective September 29, 2023. The FDA’s stated rationale: “Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities. FDA has not identified any human exposure data for drug products containing Thymosin Beta-4, Fragment. FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans.”​
• Important nuance: The FDA restriction explicitly targets the LKKTETQ fragment (TB-500); the full-length recombinant Tβ4 protein used in clinical trials (RGN-259, NL005) is evaluated under an IND with clinical safety data — a very different regulatory standing​
• RegeneRx Phase 3 (RGN-259): The ophthalmic formulation of Tβ4 has completed three Phase 3 trials and is pursuing FDA approval for dry eye — a pathway entirely separate from the compounding restriction and entirely separate from the injectable TB-500 fragment​
• 2026 reclassification: RFK Jr.’s HHS announcement that approximately 14 of 19 restricted peptides would return to legal compounding eligibility may include TB-500 — formal implementation was pending as of early 2026

WADA Status

TB-500 (and Thymosin Beta-4 in all forms) is explicitly named on the WADA 2026 Prohibited List under Section S2.2.5 (Peptide Hormones and Related Factors — Growth Factors and Growth Factor Modulators):

“Thymosin-β4 and its derivatives e.g. TB-500” — prohibited at all times, including out-of-competition

TB-500 is prohibited in all sports governed by WADA anti-doping rules, NCAA athletics (by incorporation), and all major professional sports leagues with WADA-referenced codes. The explicit naming of “e.g. TB-500” as an example derivative is unusual on the Prohibited List and reflects the awareness that TB-500 is the most widely circulated performance-adjacent form of Tβ4 in the sports supplement market.​

Preclinical Safety

TB-500 and Tβ4 have a broad and consistently favorable preclinical safety profile across multiple species, routes, and dosing regimens:

• No preclinical toxicology identified: A 2016 comprehensive review specifically stated: “The safety profile is excellent, and no preclinical toxicology has been found” — encompassing animal studies across mice, rats, pigs, and dogs​
• No tumorigenesis: Co-treatment with Tβ4 microspheres and hiPSC-derived cardiomyocytes in immunosuppressed pigs did not induce tumorigenesis at whole-body MRI evaluation​
• No cardiac arrhythmia: The same porcine model found no increase in ventricular arrhythmia with Tβ4 treatment — important given the pro-angiogenic and cardiomyocyte-proliferative effects​
• Half-life: Approximately 2.5–3 hours following subcutaneous administration in preclinical models​

Clinical Safety

• Phase I IV (84 subjects, Wang et al., 2021): No dose-limiting toxicities, no serious adverse events across multiple dose cohorts; no drug accumulation​
• Phase II dry eye trials: Zero adverse events across both randomized controlled trials using topical Tβ4; no systemic signals detected
• Phase 2 AMI trial (90 patients): Well-tolerated safety profile with IV Tβ4 administration in STEMI patients​

FDA’s Stated Safety Concern — Immunogenicity

The FDA’s concern is not about inherent Tβ4 toxicity — which is broadly favorable — but about manufacturing quality in compounded preparations:

• Injectable peptides produced without GMP oversight (as is standard for research chemical suppliers) may contain aggregates, TFA residuals, sequence variants, and other impurities that could trigger immune responses independent of the active peptide
• Immunogenicity from peptide impurities in non-GMP products is the primary safety concern, not the pharmacological activity of TB-500 itself
• The clinical-grade recombinant Tβ4 used in RegeneRx trials (with full GMP manufacture, purity characterization, and counterion control) has a well-documented clean safety profile — the gap is between that product and the uncharacterized research chemical market

Theoretical Concerns

• Pro-fibrotic paradox: Full Tβ4 is anti-fibrotic; TB-500 lacks the Ac-SDKP domain that mediates TGF-β1/Smad pathway suppression. The fragment alone may not fully replicate the parent molecule’s anti-fibrotic activity — a consideration in applications where fibrosis prevention is important​
• Actin depolymerization at high doses: Supraphysiological TB-500 concentrations could theoretically over-depolymerize actin stress fibers in non-target tissues; this effect reverses when TB-500 is cleared but warrants consideration in dose calibration​

1. Low, T.L., et al. (1981). Complete amino acid sequence of bovine thymosin beta 4. Proceedings of the National Academy of Sciences, 78(2), 1162–1166. 
2. Sosne, G., et al. (2015). Thymosin beta 4 ophthalmic solution for dry eye. Clinical Ophthalmology, 9, 1459–1466. 
3. Sosne, G., et al. (2013). Thymosin Beta 4 Eye Drops Significantly Improve Signs and Symptoms of Severe Dry Eye. Investigative Ophthalmology & Visual Science, 54(15), 6033. 
4. Crockford, D., et al. (2010). Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 1194, 179–189. 
5. Maar, K., et al. (2021). Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State. Cells, 10(6), 1343. 
6. Peng, H., et al. (2013). Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury. Frontiers in Physiology, 4, 312. 
7. Peng, H. & Shen, N., et al. (2014). Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction. American Journal of Pathology, 184(12), 3235–3247. 
8. RegeneRx Biopharmaceuticals. (2015). Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels Are Associated with Improvement of Symptoms After Stem Cell Therapy. Press release / TCTMD. 
9. Cheng, W., et al. (2021). Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of hiPSC-derived cardiomyocytes in a porcine model of AMI. Theranostics, 11(16), 7879–7895. 
10. Kassem, K.M., et al. (2019). Thymosinβ4–Ac-SDKP pathway: Any relevance for the cardiovascular system? Canadian Journal of Physiology and Pharmacology. 
11. Zuo, A., et al. (2022). The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis. Frontiers in Pharmacology, 13, 977398. 
12. Sosne, G. (2023). Thymosin Beta 4: A Potential Novel Adjunct Treatment for Bacterial Keratitis. International Immunopharmacology, 118, 109953. 
13. Wang, J., et al. (2021). Phase 1 Safety of Recombinant Thymosin Beta-4 in Healthy Volunteers. Journal of Cellular and Molecular Medicine.
14. ClinicalTrials.gov: NCT05485818 — Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction. 
15. Raw Amino. (2025). Thymosin Beta-4 and TB-500: Comparative Insights. 
16. Jeffrey Peng MD. (2026). TB-500 for Injury Recovery: What the Research Actually Shows. 
17. Delta Peptides. (2024). TB-500 (Thymosin Beta-4) Clinical Profile. 

Regulatory
18. U.S. FDA. (2023). Substances in Compounding that May Present Significant Safety Risks — Thymosin beta-4, fragment (LKKTETQ). 
19. World Anti-Doping Agency. 2026 Prohibited List, Section S2.2.5. 
20. USADA. (2025). Athlete Advisory: What’s New on the 2026 WADA Prohibited List. 
21. Safe Harbor Group. (2026). FDA’s Overreach on Compounded Peptides. 

This product page is intended for educational and informational purposes only. TB-500 (Thymosin Beta-4 Fragment, Ac-LKKTETQ-NH₂) is sold strictly as a research compound and is not intended for human consumption. TB-500 has not been approved by the FDA, EMA, or any other regulatory agency for any therapeutic indication in humans. TB-500 (Thymosin beta-4, fragment [LKKTETQ]) appears on the FDA’s Section 503A Category 2 bulk drug substance list, which currently prohibits licensed compounding pharmacies from preparing injectable TB-500 for human therapeutic use. TB-500 is explicitly prohibited by the World Anti-Doping Agency (WADA) under Section S2.2.5 of the 2026 Prohibited List as “Thymosin-β4 and its derivatives e.g. TB-500” — banned at all times, including out-of-competition, in all sports governed by WADA anti-doping rules. Human clinical trial data for TB-500 specifically is absent — the clinical evidence base (Phase 1 IV safety, Phase 2/3 dry eye, Phase 2 cardiac) pertains to the full-length recombinant Thymosin Beta-4 protein, which is a molecularly distinct compound produced under pharmaceutical GMP standards. TB-500 sold as a research chemical lacks this manufacturing control and the clinical safety data associated with it. The information presented here is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any health-related decisions. Researchers should consult applicable institutional, local, and national regulations before use.